Ibrutinib

Ibrutinib Comprehensive User Guide

Table of Contents

• 1. Product Overview & Specifications
• 2. Clinical Applications & Mechanism
• 3. Comparative Analysis with BTK Inhibitors
• 4. Clinical Trial Insights & Protocols
• 5. Real-World Application Cases
• 6. Inquiry & Procurement Guidance

1. Product Overview & Specifications

2. Clinical Applications & Mechanism

Mechanism: Covalently binds to BTK tyrosine kinase, inhibiting B-cell receptor signaling pathways critical for malignant B-cell survival.

Key Indications:

• Relapsed/Refractory CLL (83% response rate in phase III trials)
• MCL with ≥1 prior therapy (68% overall response rate)
• WM as primary therapy (90% 2-year progression-free survival)

3. Comparative Analysis with BTK Inhibitors

4. Clinical Trial Insights & Protocols

MIT Regimen (2025 Update):

• Combination: High-dose Methotrexate + Ibrutinib + Temozolomide
• PCNSL Patients: 78% complete response rate
• ctDNA Monitoring: 92% predictive accuracy for relapse

MCL Combination Therapy:

• Ibrutinib + Venetoclax: 18-month PFS 81% vs 52% monotherapy

5. Real-World Application Cases

Case 1: Zhejiang Cancer Hospital (2024)
63yo MCL patient achieved 22-month remission with Ibrutinib monotherapy, maintaining ECOG 1 status.

Case 2: Peking Union Medical College Hospital (2025)
WM patient cohort (n=47) showed 93% hematological response with median time to response 4.1 weeks.

6. Inquiry & Procurement Guidance

For clinical protocols, pricing, and supply chain solutions:

Email: info@vivalr.com
Tel: (86) 15866781826

Global lead time: 7-14 business days for research-grade quantities.
Minimum Order Quantity: 10 treatment cycles (300 capsules).